Key Takeaways
Boston Scientific Corp. is making a major push into the growing market for heart valve replacement, investing $1.5 billion for a nearly 34 percent stake in MiRus LLC to gain access to its novel transcatheter aortic valve replacement system. The deal positions Boston Scientific to challenge established players in a lucrative field.
"The occurrence and recognition of aortic stenosis is growing rapidly and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio," Lance Bates, executive vice president at Boston Scientific, said in a statement. He added that the SIEGEL valve's design and early clinical results "may set it apart from currently available technology."
The agreement gives Boston Scientific (NYSE: BSX) an exclusive option to acquire the MiRus TAVR business outright for an additional $3 billion, contingent on clinical and regulatory milestones. The SIEGEL TAVR system, an investigational device not yet approved for sale, is currently being evaluated in a pivotal trial of up to 1,025 patients with severe, symptomatic aortic stenosis. The investment is expected to be immaterial to Boston Scientific's adjusted earnings per share in 2026.
At the heart of the deal is the SIEGEL valve, designed to compete with existing devices from companies like Edwards Lifesciences. The valve is built on a proprietary rhenium alloy, making it nickel-free, and features a delivery system that can be inserted through an 8 French expandable sheath. This is approximately 50 percent smaller than the sheath used for the Edwards eSheath+ introducer, potentially minimizing vascular injuries during the procedure. MiRus founder and CEO Jay Yadav, M.D., noted the device has received "enthusiastic feedback from physician investigators for its less invasive delivery."
This article is for informational purposes only and does not constitute investment advice.
